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A B S T R A C T
Background: Low-grade inflammation occurs in a subgroup of patients with Major Depressive Disorder (MDD) and
may be associated with response to antidepressant medications. The Neutrophil to Lymphocyte Ratio (NLR) and
total White Blood cell Count (WBC) are markers of systemic inflammation which have not been investigated as
predictors for outcome to pharmacotherapy in unipolar depression yet. Moreover, the association between
inflammation and treatment response has not been studied in unipolar Psychotic Depression (PD). We conducted
an exploratory analysis to examine the prognostic significance of NLR and WBC in pharmacotherapy of PD.
Methods: Baseline NLR and WBC were examined in their association with response to seven weeks of treatment
with antidepressants (venlafaxine or imipramine) and the combination of an antidepressant with an antipsychotic
(venlafaxine plus quetiapine) in 87 patients with PD. Logistic regression models were adjusted for age, gender,
Body Mass Index (BMI), depression severity, duration of the current episode and number of previous depressive
episodes. Secondary outcomes were remission of depression and disappearance of psychotic symptoms.
Results: Higher NLR was associated with increased response to pharmacotherapy (Exp(B) 1.66, 95 % CI 1.03–2.66,
p ¼ 0.036), but not with remission of depression or disappearance of psychotic symptoms. WBC was not asso-
ciated with any of the outcome measures.
Conclusion: NLR may be a novel, inexpensive and widely available biomarker associated with response to phar-
macotherapy in PD. The association between white blood cell measures and treatment outcome should be further
investigated for different types of antidepressants in PD and in non-psychotic MDD.
1. Introduction
Low-grade inflammation occurs in 25–50 % of patients with Major
Depressive Disorder (MDD), reflected by elevated pro-inflammatory
markers, such as C-Reactive Protein (CRP) and the cytokines Tumor
Necrosis Factor alpha (TNF-α) and Interleukin (IL)-6 (Miller, 2020;
Dantzer et al., 2008; Miller and Raison, 2016; Pariante, 2017). Several
studies suggest an association between pre-treatment inflammation and
response to antidepressant medications (Strawbridge et al., 2015; Liu
et al., 2020; Arteaga-Henriquez et al., 2019; Pantovic-Stefanovic et al.,
2018), although no consensus on this has been reached.
Most studies to inflammation in MDD focus on cytokines or CRP but
also other markers can indicate inflammation, including white blood cell
counts and ratios (Mayadas et al., 2014). Both the Neutrophil to
Lymphocyte Ratio (NLR), the ratio of the two most common types of
white blood cells, and total White Blood cell Count (WBC) are
well-established markers of systemic inflammation and can be easily
derived from a white blood cell essay (Templeton et al., 2014; Duivis
et al., 2013). Meta-analyses demonstrate that NLR is elevated in MDD
and in several other psychiatric disorders, such as bipolar disorder and
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schizophrenia, compared to healthy controls (Mazza et al., 2018, 2019;
Jackson and Miller, 2020). Higher NLR has been associated with higher
depression severity in MDD and suicidality in MDD and bipolar disorder
(Aydin Sunbul et al., 2016; Velasco et al., 2020; Kayhan et al., 2017;
Ivkovic et al., 2016; Brinn and Stone, 2020). Also, elevatedWBC has been
reported in MDD but less consistently compared to NLR (Duivis et al.,
2013; Beydoun et al., 2016; German et al., 2006; Shafiee et al., 2017;
Kobrosly and van Wijngaarden, 2010). So far, no studies investigated the
association between NLR or WBC with response to antidepressant med-
ications in unipolar depression (Duivis et al., 2013; Mazza et al., 2018;
German et al., 2006).
The present study aimed to assess whether NLR and WBC at baseline
are associated with response to pharmacotherapy in unipolar Psychotic
Depression (PD), i.e. a severe subtype of MDD with additional psychotic
features (hallucinations and/or delusions) (American Psychiatric Asso,
2013; Dold et al., 2019). PD is associated with higher cortisol levels
compared to non-psychotic MDD (Carroll et al., 2007; Contreras et al.,
2007). Since prolonged elevated cortisol might initiate inflammation, PD
is an interesting condition to study the association between inflammation
and treatment outcome (Pariante, 2017; Anacker et al., 2011). NLR and
WBC, as well as other pro-inflammatory markers, have not been inves-
tigated in relation to outcome to pharmacotherapy in PD yet. Since this
study was conducted as an exploratory analysis, no a-priori hypotheses
were formulated.
2. Materials and methods
2.1. Study design
This study is a secondary analysis of the DUDG-study (Wijkstra et al.,
2010). The DUDG-study is a double-blind randomized controlled trial
comparing treatment outcome to venlafaxine, imipramine or venlafaxine
plus quetiapine in 122 patients with PD.
2.2. Patients
Patients were aged 18–65 years and had a diagnosis of unipolar MDD
with psychotic features according to DSM-IV-TR criteria (American
Psychiatric Asso, 2000). At baseline, patients had a score of 18 on the
Hamilton Rating Scale for Depression (HAM-D-17) (Hamilton, 1960),
indicating severe depression, and they were free of psychotropic medi-
cation for at least 4 days. Patients were randomized to seven weeks
double blind treatment with venlafaxine (max. 375mg/day), imipramine
(plasma levels 200–300 μg/L) or venlafaxine plus quetiapine (max.
375 mg/day, and max. 600 mg/day respectively). We included only
patients who actually started study medication in the original study.
Exclusion criteria were an acute clinical indication for electrocon-
vulsive therapy, intellectual disability, alcohol or substance abuse within
3 months of enrollment, any serious somatic illness or somatic medica-
tion potentially affecting mood, contra-indications for study medication
or previous adequate treatment of the current depressive episode with
imipramine or venlafaxine. In agreement with previous studies, patients
with very low (<4 ∙ 109/L) or high WBC (>12 ∙ 109/L) at baseline,
suggestive for somatic illness, or obesity (BMI >30) were excluded
(Velasco et al., 2020; Kayhan et al., 2017; Demircan et al., 2016; Cai
et al., 2017; Demir et al., 2015; Hotamisligil, 2006).
2.3. White blood cell measures
At baseline blood samples were taken from which white blood cell
counts were assessed in all participants of the original study. Samples
were analyzed at the study sites using the Abbott Cell-Dyn Sapphire,
Sysmex XE-5000, Sysmex XE-2100 or Siemens ADVIA 120, depending on
the location and date of inclusion. For these hematology analyzers a good
inter-instrument concordance for white blood cell counts has been
demonstrated (Bruegel et al., 2015; Kang et al., 2008). WBC was defined
as the sum of the absolute neutrophil, lymphocyte, eosinophil, basophil
and monocyte counts. NLR was computed by dividing the absolute
neutrophil count through the absolute lymphocyte count.
2.4. Outcome measures
The primary outcome measure was treatment response, defined as
50 % decrease in HAM-D-17 score after seven weeks of treatment.
Secondary outcome measures were remission of depression, defined as a
HAM-D-17 score 7, and remission of psychotic symptoms, defined as
absence of delusions and hallucinations after seven weeks of treatment.
Psychotic features were assessed on the basis of clinical impression, both
at baseline and at the final study visit, and were scored dichotomously
(present or absent).
2.5. Univariate analyses
Chi-square tests were used to compare dichotomous baseline char-
acteristics and unpaired t-tests to compare continuous baseline variables.
Associations were computed between baseline characteristics and white
blood cell markers by Pearson's or Spearman's correlations where
appropriate.
2.6. Multivariate analyses
Logistic regression analyses were conducted to study multivariate
associations between white blood cell markers and the outcome mea-
sures. Concerning drop-outs, the last observation carried forward (LOCF)
methodwas applied. All logistic regression analyses were adjusted for the
most important potential confounders in accordance with previous
research on NLR and WBC in MDD: gender, age, severity of depression
and number of previous depressive episodes (Mazza et al., 2018; Aydin
Sunbul et al., 2016; Huguet et al., 2019; Arabska et al., 2018).
Additionally, interaction effects were studied between NLR, WBC and
medication types regarding treatment response as the primary outcome
measure. Interaction terms were computed as the product of NLR or WBC
and venlafaxine, imipramine and venlafaxine plus quetiapine respec-
tively. First, venlafaxine, imipramine and venlafaxine plus quetiapine, as
well as the interaction terms of NLR and these medication types were
added to the logistic regression model for NLR, using treatment response
as dependent variable. Second, a similar procedure was performed for
WBC. Analyses were conducted in SPSS version 26 (IBM Corp, Armonk,
NY).
3. Results
From the 122 patients participating in the original study, 35 were
excluded for the current analysis: four because they did not start study
medication, 17 because of missing neutrophil or lymphocyte counts,
three because of WBC <4 ∙ 109/L, five because of WBC >12 ∙ 109/L and
six because of obesity. Hence, analyses were conducted for 87 patients,
which is 71 % of the original sample: 27 (31 %) in the venlafaxine group,
31 (36 %) in the imipramine group and 29 (33 %) in the venlafaxine plus
quetiapine group.
The 87 patients included in the current analysis did not differ
significantly from the 35 patients excluded from the original sample
regarding age (t(120)¼1.12, p¼ 0.60), gender (X2 (1, n¼ 122)¼ 0.10,
p ¼ 0.75), number of previous episodes (t(120) ¼ 0.45, p ¼ 0.65),
duration of the current episode (t(43.8) ¼ 1.03, p ¼ 0.31), depression
severity (t(120)¼<0.01, p ¼ 1.00) and treatment response (X2 (1,
n ¼ 118) ¼ 1.21, p ¼ 0.27). Therefore, patients in this study can be
considered representative for the original study population.
Patient characteristics are presented in Table 1. At baseline, mean
NLR was 2.58 (SD 1.53) and mean WBC was 7.15 ∙ 109/L (SD 1.70).
Number of previous episodes was positively correlated with WBC but not
with NLR. There were no significant associations between NLR or WBC
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and gender, age, severity of depression, duration of the current episode
and BMI.
After 7 weeks of treatment, 52 out of 87 patients (60 %) reached
treatment response, 29 (33 %) attained remission of depression and
psychotic features remitted in 59 patients (68 %).
Multiple logistic regression analyses were used to compute associa-
tions between white blood cell markers and outcome measures. As pre-
sented in Table 2, higher NLR at baseline was associated with increased
response after seven weeks of pharmacotherapy. NLR was not associated
with remission of depression or psychotic symptoms. WBC was not
associated with any of the outcome measures.
Interaction effects between NLR or WBC and medication types were
examined for treatment response as the primary outcome measure. By
conducting logistic regressions, adjusted for age, gender, baseline HAM-
D-17 score and number of previous episodes, none of the interaction
terms was significantly associated with treatment response (data not
shown). We concluded that there were no significant interactions be-
tween NLR or WBC and type of study medication.
4. Discussion
Low-grade inflammation occurs in a subpopulation of MDD patients
and may be associated with response to antidepressant medications
(Miller, 2020; Strawbridge et al., 2015; Liu et al., 2020; Arteaga-Henri-
quez et al., 2019). In this study we explored whether pre-treatment NLR
and WBC, inexpensive and widely available hematological markers of
systemic inflammation, are associated with outcome to seven weeks of
pharmacotherapy in PD. Our results indicate that higher NLR at baseline
is associated with increased response to pharmacotherapy in PD, while it
was not associated with remission of depression or disappearance of
psychotic symptoms. WBC was not associated with any of the outcome
measures. No significant interaction effects were found between NLR or
WBC and medication types. Mean NLR and mean WBC were in line with
values reported earlier in a small subset of 14 PD patients (Kayhan et al.,
2017). WBC was positively related to the number of previous depressive
episodes, which has been reported before and was adjusted for in our
logistic regression analyses (Duivis et al., 2013).
Previous findings regarding the prognostic significance of low-grade
inflammation for response to antidepressant medications vary (Straw-
bridge et al., 2015; Arteaga-Henriquez et al., 2019; Kohler-Forsberg
et al., 2019). A number of studies report that MDD patients with lower
levels of inflammation respond better to serotonergic antidepressants,
whereas patients with higher levels of inflammation respond better to
noradrenergic, dopaminergic or glutamatergic antidepressants (Straw-
bridge et al., 2015; Liu et al., 2020; Arteaga-Henriquez et al., 2019). For
instance, data of the GENDEP and COMED trials show that patients with
CRP <1 mg/L respond better to the serotonergic antidepressant escita-
lopram and patients with CRP >1 mg/L respond better to the norad-
renergic antidepressant nortriptyline or the dopaminergic antidepressant
bupropion (Arteaga-Henriquez et al., 2019; Jha et al., 2017; Uher et al.,
2014).
In our study, all patients were treated with (at least) venlafaxine or
imipramine, both antidepressants with combined serotonergic and
noradrenergic effects. One group was treated with venlafaxine plus
quetiapine, an antipsychotic of which its active metabolite, norquetia-
pine, functions as a selective noradrenergic reuptake inhibitor (Lopez--
Munoz and Alamo, 2013). We observed no interaction effects between
the white blood cell measures and any of the treatment groups, possibly
due to similarities between the treatment mechanisms or because of the
relatively small treatment groups. Therefore, the positive association
between NLR and treatment response in this study might be explained by
either the noradrenergic effects of the studymedications or the combined
serotonergic and noradrenergic effects of imipramine, venlafaxine and
quetiapine (Jha et al., 2017; Uher et al., 2014).
It is unclear whether our findings can be fully generalized to non-
psychotic MDD. PD is strongly associated with high cortisol levels,
whereas elevated cortisol levels are not consistently found in non-
psychotic MDD (Carroll et al., 2007; Contreras et al., 2007). Cortisol is
a potent anti-inflammatory hormone directly increasing neutrophils and
therefore the NLR (Pariante, 2017; Anacker et al., 2011). However, in
case of prolonged elevated cortisol levels glucocorticoid resistance may
occur, in which cortisol and NLR appear unrelated (Pariante, 2017;
Anacker et al., 2011; Cohen et al., 2012; Kronfol et al., 1985). If gluco-
corticoid resistance occurs, the anti-inflammatory function of cortisol is
impaired and pro-inflammatory cytokines and NLR may rise, as observed
in a subpopulation of MDD patients (Pariante, 2017; Anacker et al., 2011;
Cohen et al., 2012; Kronfol et al., 1985). The interplay between cortisol,
NLR and other pro-inflammatory markers requires further investigation
in PD and in other types of depression.
In contrast to NLR, WBC was not predictive for treatment outcome.
Previously, WBC was found not to predict response to quetiapine or
lithium in bipolar disorder (Kohler-Forsberg et al., 2019). Generally, NLR
is considered a superior indicator of pro-inflammatory activity compared
to WBC, since NLR reflects the relative activity of two immunological
pathways: neutrophils function as the first line of immunological defense
and lymphocytes have a prominent immunoregulatory role and reflect
general health and physiological stress (Mayadas et al., 2014).
Potentially, the association between NLR and response to pharma-
cotherapy could play a role in personalized pharmacotherapy for PD. PD
is associated with a worse clinical course of illness, higher recurrence,
higher mortality and lower response to antidepressant medications than
non-psychotic MDD (Dold et al., 2019; Wijkstra et al., 2015). Therefore,
Table 1
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number of previous episodes and duration of the current episode.
Table 2
NLR and WBC as prognostic markers for treatment response, remission of
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and number of previous episodes.
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adequate predictors for outcome to pharmacotherapy are highly needed.
Besides, also in non-psychotic MDD efficacy of antidepressant medica-
tions is modest since response to the first prescribed antidepressant oc-
curs in only half of the patients (Cipriani et al., 2018; Rush et al., 2006,
2011). Moreover, onset of response is generally delayed and adverse
effects are common (Dold et al., 2019; Wijkstra et al., 2015; Jaaskelainen
et al., 2018). Efficacy and tolerability of antidepressant medications may
be increased by personalized pharmacotherapy, i.e., precision medicine
in which therapy is adjusted to individual patient characteristics. For
this, new studies and further secondary analyses using data of clinical
trials will be needed to gain a better understanding of how the choice for
antidepressant medications can be personalized effectively (Labermaier
et al., 2013; Bayes and Parker, 2019).
A strength of our study is that it consists of a relatively large and
homogeneous sample of well-defined PD patients. All patients were free
of psychotropic medication at baseline and were treated according to
predefined doses or plasma concentrations for seven weeks. Depression
severity was assessed weekly using the HAM-D-17. A limitation is that
the study population is still relatively small to investigate relations be-
tween biomarkers and treatment outcome. Also, in most studies on NLR
and WBC patients who smoke (>15 cigarettes per day) and patients with
somatic comorbidities or comedications affecting white blood cell counts
are excluded (Mazza et al., 2018). We were not able to adjust for
smoking, use of comedications, diet and ethnicity, as these data were not
available for all patients. However, patients with serious somatic illness
were excluded in the original study and most patients were likely Cau-
casians. Furthermore, hormones, e.g., cortisol levels, and metabolites of
study medications, e.g., norquetiapine, were not measured and therefore
we were not able to investigate their influence on the association be-
tween white blood cell markers and outcome measures.
5. Conclusion
In conclusion, we found preliminary evidence that higher pre-treat-
ment NLR is associated with increased response to pharmacotherapy in
PD. We found no associations between WBC and treatment outcome.
Future research is needed to replicate our findings and to investigate the
prognostic significance of white blood cell measures for response to
different types of pharmacotherapy in PD and in non-psychotic MDD.
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